IFNα receptor 2 agonist
RO 8191 is an IFNα receptor 2 (IFNAR2) agonist (EC50 = 0.2 μM). RO 8191 induces phosphorylation and activation of STAT1 and STAT2. RO 8191 inhibits hepatitis C (HCV) cell culture-produced infectious particles and HCV subgenomic replicon (IC50 values 0.20 μM and 0.17 μM, respectively) and inhibits hepatitis B virus replication in cell cultures (IC50 = 0.1 μM). In an animal model RO 8191 inhibits prion invasion and prolongs survival; it also reverses the inhibitory effect of integrin β6 (ITGB6) on the JAK/STAT3 signaling and the epithelial-to-mesenchymal transition pathway and inhibits the proliferation, invasion, and migration of cervical cancer cells. Orally bioavailable.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-151793 |
| Réf. fabricant | 18787066 |
| Nom chimique ou matériau | 8-(1,3,4-Oxadiazol-2-yl)-2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8 ]naphthyridine |
| CAS | 691868-88-9 |
| Quantité | 10 mg |
| Cible | IFN-alpha/beta R2 |
| Formule moléculaire | C<sub>14</sub>H<sub>5</sub>F<sub>6</sub>N<sub>5</sub>O |
| Pureté | 0.98 |
